For the year ending 2025-12-31, ACHV had $8,176K increase in cash & cash equivalents over the period. -$49,468K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -54,648 |
| Depreciation and amortization note 4 | 228 |
| Stock-based compensation note 10, note 10, note 10 and note 10 | 8,761 |
| Shares issued as settlement with trade vendor | 0 |
| Accrued interest on svb convertible debt note 8 | 0 |
| Amortization of 2024 svb convertible term loan transaction costs note 8 | 52 |
| Change in fair value of contingent consideration note 4 and note 5 | 408 |
| Prepaid expenses and other assets-Nonrelated Party | 1,204 |
| Prepaid expenses and other assets-Related Party | 193 |
| Accounts payable-Nonrelated Party | -1,091 |
| Accounts payable-Related Party | 8 |
| Accrued liabilities other-Nonrelated Party | 25 |
| Accrued liabilities other-Related Party | 6 |
| Accrued clinical liabilities | -709 |
| Accrued compensation | -1,108 |
| Lease obligation | 0 |
| Net cash used in operating activities | -49,465 |
| Proceeds from exercise of warrants note 10 | 1,385 |
| Proceeds from employee stock purchase plan note 10 | 0 |
| Taxes paid related to net share settlement of equity awards | 0 |
| Proceeds from private placement, net of issuance costs note 10-November2022Private Placement | 0 |
| Proceeds from registered direct offering, net of issuance costs-February2024Registered Direct Offering | 0 |
| Proceeds from june 2025 public offering, net of issuance costs note 7b-June2025Public Offering | 41,138 |
| Proceeds from june 2025 public offering exercise of overallotment option, net of issuance costs note 10b | 4,004 |
| Receipt of 2024 svb convertible term loan second tranche note 6 and note 8 | 5,000 |
| Net cash provided by financing activities | 51,527 |
| Purchase of property and equipment | 3 |
| Loss on disposal of property and equipment | 1 |
| Realized gain on investments | 4 |
| Purchase of investments | 24,755 |
| Maturities of investments | 30,866 |
| Net cash provided by (used in) investing activities | 6,111 |
| Effect of exchange rate changes on cash | 3 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 8,176 |
| Cash, cash equivalents and restricted cash at beginning of year | 12,773 |
| Cash, cash equivalents and restricted cash at end of year | 20,949 |
ACHIEVE LIFE SCIENCES, INC. (ACHV)
ACHIEVE LIFE SCIENCES, INC. (ACHV)